Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02181712 · ClinicalTrials.gov registry record · Phase 1
Mesenchymal Stem Cell Therapy for Lung Rejection
A Phase 1 study of Bronchiolitis Obliterans and Lung Transplant Reject, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT02181712 is a Phase 1 study of Bronchiolitis Obliterans and Lung Transplant Reject that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants, below the 407-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02181712, a Phase 1 study of Bronchiolitis Obliterans and Lung Transplant Reject, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the safety and feasibility of mesenchymal stem cells therapy in patients with transplant related bronchiolitis obliteran syndrome (BOS)
Conditions Studied
Interventions
- BIOLOGICAL Mesenchymal stem cell 0.5
- BIOLOGICAL Mesenchymal stem cell 1.0
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-07 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02181712
The ClinicalTrials.gov registry entry for NCT02181712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 9 other Bronchiolitis Obliterans trials with a reported enrollment target (95% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bronchiolitis Obliterans appearing as the primary indexed condition, and to 2 interventions - of which Mesenchymal stem cell 0.5 is the first listed.
NCT02181712 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02181712 about?
NCT02181712 is a clinical study titled "Mesenchymal Stem Cell Therapy for Lung Rejection". To assess the safety and feasibility of mesenchymal stem cells therapy in patients with transplant related bronchiolitis obliteran syndrome (BOS)
What is the current status of trial NCT02181712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-07. Estimated completion is 2021-08-12.
What conditions does trial NCT02181712 study?
This clinical trial studies the following conditions: Bronchiolitis Obliterans, Lung Transplant Reject.
What interventions are being tested in trial NCT02181712?
The interventions under investigation include: Mesenchymal stem cell 0.5 (BIOLOGICAL), Mesenchymal stem cell 1.0 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02181712?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02181712 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchiolitis Obliterans
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hp129 Xenon Imaging and BOS in Lung Transplantation
COMPLETED · Phase 1
-
TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
RECRUITING
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Evaluating Clonogenic Epithelial Cell Populations in Patients With Bronchiolitis Obliterans Syndrome
RECRUITING
-
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.